Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.

ABSTRACT:

Purpose

We have clinically evaluated a DNA fusion vaccine to target the HLA-A*0201-binding peptide CAP-1 from carcinoembryonic antigen (CEA_605-613) linked to an immunostimulatory domain (DOM) from fragment C of tetanus toxin.

Experimental design

Twenty-seven patients with CEA-expressing carcinomas were recruited: 15 patients with measurable disease (arm-I) and 12 patients without radiological evidence of disease (arm-II). Six intramuscular vaccinations of naked DNA (1 mg/dose) were administered up to week 12. Clinical and immunologic follow-up was up to week 64 or clinical/radiological disease.

Results

DOM-specific immune responses demonstrated successful vaccine delivery. All patients without measurable disease compared with 60% with advanced disease respo

SUBMITTER: McCann KJ 

PROVIDER: S-EPMC5330406 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature